You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Express Scripts
AstraZeneca
Dow
McKesson

Last Updated: August 7, 2020

DrugPatentWatch Database Preview

Litigation Details for Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)

Docket   Start Trial Date Filed 2017-06-30
Court District Court, N.D. West Virginia Date Terminated
Cause 35:271 Patent Infringement Assigned To Irene Patricia Murphy Keeley
Jury Demand None Referred To James P. Mazzone
Parties BIOGEN INTERNATIONAL GMBH; BIOGEN MA, INC.; MYLAN PHARMACEUTICALS INC.
Patents 10,029,015; 6,509,376; 6,926,907; 7,320,999; 8,013,002; 8,399,514; 8,759,393; 9,018,017; 9,024,096
Attorneys Aaron G. Clay; Adam S Ennis; Andrew E. Renison; Brandon M. White; Courtney M. Prochnow; David L. Anstaett; Emily J. Greb; Eric J. Fues; Gordon H. Copland; James B. Monroe; James F. Companion; Jeanette M. Roorda; John E. Nappi; Laura P Masurovsky; Lauren J. Dowty; Li Feng; Michael A. Chajon; Paul W. Browning; Sanya Sukduang; Shannon M Bloodworth; Travis L. Zeik; William J O'Brien
Firms Finnegan Henderson Farabow Garrett and Dunner; Perkins Coie LLC; Perkins Coie LLP; Perkins Coie, LLP; Schrader Companion Duff & Law, PLLC; Steptoe & Johnson PLLC - Bridgeport; Steptoe & Johnson PLLC, Cannonsburg
Link to Docket External link to docket
Small Molecule Drugs cited in Biogen International GMBH v. Mylan Pharmaceuticals Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in Biogen International GMBH v. Mylan Pharmaceuticals Inc.

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)

Date Filed Document No. Description Snippet Link To Document
2017-06-30 1 Complaint 393 patent”) and 8,399,514 (“the ‘514 patent”) arising under the patent laws of the United States, Title…- 376 Patent, # 2 Exhibit B - 999 Patent, # 3 Exhibit C - 001 Patent, # 4 Exhibit D - 840 Patent, # 5 …is an action for patent infringement of U.S. Patent Nos. 6,509,376 (“the ‘376 patent”), 7,320,999 (“the…“the ‘999 patent”), 7,619,001 (“the ‘001 patent”), 7,803,840 (“the ‘840 patent”), 8,759,393 (“the ‘393…5 Exhibit E - 393 Patent, # 6 Exhibit F - 514 Patent, # 7 Civil Cover Sheet)(lmm) (Entered: 06/30/2017 External link to document
2018-10-12 142 Status Report infringement of U.S. Patent Nos. 6,509,376 (“the ’376 patent”), 7,320,999 (“the ’999 patent”), 7,619,001 … (“the ’001 patent”), 7,803,840 (“the ’840 patent”), 8,759,393 (“the ’393 patent”) and 8,399,514 … the patents-in-suit. The ’393 patent has expired. It is Mylan’s position that this patent should be…partes review (“IPR”) of Biogen’s ’514 patent. Biogen’s Patent Owner’s Preliminary Response is due on…for regulatory patent term extension (“PTE”) on the ’376, ’999, ’001, and ’840 patents. Under the relevant External link to document
2019-02-05 196 Stipulation and Order affirmative defenses related to U.S. Patent Nos. 6,509,376; 7,320,999; 7,803,840; and 8,759,393. The parties…counterclaims and affirmative defenses as to U.S. Patent Nos. 7,619,001 and 8,399,514. Signed by Senior …June 2017 22 June 2020 1:17-cv-00116 Patent - Abbreviated New Drug Applications (ANDA) External link to document
2019-10-08 288 Order Parties to this patent infringement case involving U.S. Patent Nos. 8,399,514 (“the °514 patent”) and 7,619,001… 15-16 of the °514 patent and claims 1-3, 6-9, 12-19, and 22-24 of the *001 patent under 35 U.S.C. § 271…and 15-16 of the 514 patent and claims 1-3, 6-9, 12-19, and 22-24 of the °001 patent are not invalid and…7,619,001 (‘the 001 patent”); WHEREAS the Parties wish to narrow the issues in this litigation; WHEREAS…that it will not assert claims 17-19 of the 514 patent against Mylan (see ECF 102); THEREFORE, IT IS External link to document
2020-01-03 299 Notice (Other) Rajendra Kumar Joshi; Hans- 6,509,376 1/21/03 United…invalidate U.S. Patent Nos. 7,619,001 (“the ’001 patent”) and 8,399, 514 (“the ’514 patent”) (collectively… the “patents-in-suit”) and/or show the state of the art relative to the asserted patents. … Patents and File Histories Date of Issue/ Patent/Patent… Date of Issue/ Patent/Patent Publication Country of Publication External link to document
2020-01-09 308 Other Document 13:23-14:12 21:15-17 22:10-14 28:10-29:15 29:19-23 30:13-18 30:20-31:19 …2017 22 June 2020 1:17-cv-00116 835 Patent - Abbreviated New Drug Applications (ANDA) External link to document
2020-01-16 323 Other Document asserted claims of United States Patent No. 8,399,514 (“the ’514 patent”), on issues including invalidity…invalidity of the asserted claims of the ’514 patent, on issues including the lack of any secondary …invalidity of the asserted claims of the ’514 patent, including the lack of any secondary considerations…United States International Trade Commission, the Patent Trial and Appeal Board, and on matters before various…Hofmann has also been engaged by the United States Patent and Trademark Case 1:17-cv-00116-IMK-JPM Document External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Dow
Baxter
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.